iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis
November 24 2020 - 7:30AM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech
innovator and biologics contract manufacturing organization, today
announced that the United States Patent and Trademark Office has
issued U.S. Patent No. 10,844,392, entitled “Materials and Methods
for Producing Endostatin Fusion Polypeptides in Plant Cells,”
which, amongst other claims, covers a novel expression cassette
that enhances the yield of endostatin fragments and variants using
iBio’s
FastPharming® System.
The claims in the patent are foundational to
iBio’s work on its antifibrotic therapies given that the
technologies enhance the expression and quality of
endostatin-derived E4 antifibrotic peptides fused to human IgG1
when produced in plants. The Company is developing such a molecule
as “IBIO-100” for the treatment of fibrotic disorders, including
systemic scleroderma and idiopathic pulmonary fibrosis. The ‘392
Patent contains 19 claims and expires in June 2036.
“This patent, and the technologies it covers,
advances our work on therapeutic candidates for treating fibrotic
disorders by increasing the number of antifibrotic peptide variants
that we may select for clinical development,” said Tom Isett,
Chairman & CEO of iBio. “iBio can also apply certain claims to
other IgG-based molecules manufactured using our
FastPharming System, thereby creating the
opportunity to secure additional intellectual property based upon
composition of matter.”
iBio plans to conduct IND-enabling studies on
IBIO-100 in 2021.
About
iBio, Inc.
iBio is a global leader in plant-based biologics
manufacturing. Its FastPharming® System combines
vertical farming, automated hydroponics, and glycan engineering
technologies to rapidly deliver high-quality monoclonal antibodies,
vaccines, bioinks and other proteins. The Company’s subsidiary,
iBio CDMO LLC, provides FastPharming Contract
Development and Manufacturing Services. iBio’s
Glycaneering Development Service™ includes an
array of new glycosylation technologies for engineering
high-performance recombinant proteins. Additionally, iBio is
developing proprietary products, which include IBIO-100 for the
treatment of fibrotic diseases, and vaccines for infectious
diseases. For more information, visit www.ibioinc.com.
FORWARD-LOOKING
STATEMENTSCertain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding developing “IBIO-100”
for the treatment of fibrotic disorders, including systemic
scleroderma and idiopathic pulmonary fibrosis, securing additional
intellectual property based upon composition of matter by applying
certain claims to other IgG-based molecules manufactured using our
FastPharming System and plans to conduct IND-enabling studies on
IBIO-100 in 2021. While the Company believes these forward-looking
statements are reasonable, undue reliance should not be placed on
any such forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are subject to various risks and uncertainties, many of
which are difficult to predict that could cause actual results to
differ materially from current expectations and assumptions from
those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
Company’s ability to conduct additional investigational new
drug-enabling studies in the first half of 2021 as planned, the
Company’s ability to obtain regulatory approvals for
commercialization of its product candidates, including its COVID-19
vaccines, or to comply with ongoing regulatory requirements,
regulatory limitations relating to its ability to promote or
commercialize its product candidates for specific indications, the
Company’s ability to enroll patients and complete clinical trials
on time and achieve desired results and benefits as expected,
acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of products, its ability
to maintain its license agreements, the continued maintenance and
growth of its intellectual property portfolio, its ability to
establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities, competition, its ability to retain its key
employees or maintain its NYSE American listing, and the other risk
factors discussed in the Company’s most recent Annual Report on
Form 10-K and the Company’s subsequent filings with the SEC,
including subsequent periodic reports on Forms 10-Q and 8-K. The
information in this release is provided only as of the date of this
release, and we undertake no obligation to update any
forward-looking statements contained in this release on account of
new information, future events, or otherwise, except as required by
law.
Contacts:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580 skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024